A photo of Brian Weiss.

Medical Director, Solid Tumor Program

Director, Neuroblastoma Program

Associate Director for Safety and Compliance

Professor, UC Department of Pediatrics

513-636-9863

513-636-3549

Board Certified

My Biography & Research

Biography

I specialize in caring for children with neuroblastoma and neurofibromatosis type 1 (NF1) related plexiform neurofibromas. I research novel therapies and targeted radiotherapy to treat neuroblastoma, particularly high-risk neuroblastoma. I am also investigating the development of targeted therapies for NF1 related plexiform neurofibromas.

My interest in clinical practice and research stems from my love and desire to care for children and help their families. I have a strong determination to make a difference in the lives of every individual. The ultimate research goal is to find a cure for these disorders.

In addition, in my role as associate director for Safety and Compliance, I have spearheaded efforts to reduce chemotherapy errors. In this effort, I have led a multi-disciplinary team that has significantly and consistently improved our safety around chemotherapy.

I am certified in Pediatrics (1996, 2002) and Pediatric Hematology-Oncology (2000, 2007, 2019) by the National Medical Board. My work is published in many well-respected journals, including The New England Journal of Medicine, Bone Marrow Transplantation, BMJ Quality and Safety, Pediatric Blood and Cancer, Clinical Cancer Research, American Journal of Medical Genetics and the Journal of Pediatric Gastroenterology and Nutrition.

Clinical Interests

Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Neuroblastoma, Neurofibromatosis, Rasopathy

Research Divisions

Oncology, Cancer and Blood Diseases

My Locations

My Education

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.

My Publications

Selected Publication

High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Jodele, S; Dandoy, CE; Myers, K; Wallace, G; Lane, A; Teusink-Cross, A; Weiss, B; Davies, SM. Bone Marrow Transplantation. 2018; 53:1311-1318.

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Granger, M; Naranjo, A; Bagatell, R; DuBois, SG; McCune, JS; Tenney, SC; Weiss, BD; Mosse, YP; Asgharzadeh, S; Grupp, SA; et al. 2021.

Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis. Emberesh, M; Rubinstein, JD; Young, J; Benoit, SW; Dandoy, CE; Weiss, BD. Pediatric Blood and Cancer. 2021; 68.

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al. Journal of Clinical Oncology. 2021; 39:797-806.

Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma. Sung, AJ; Weiss, BD; Sharp, SE; Zhang, B; Trout, AT. Pediatric Radiology. 2021.

Selumetinib in Children with Inoperable Plexiform Neurofibromas. Gross, AM; Wolters, PL; Dombi, E; Baldwin, A; Whitcomb, P; Fisher, MJ; Weiss, B; Kim, A; Bornhorst, M; Shah, AC; et al. New England Journal of Medicine. 2020; 382:1430-1442.

Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R. Pediatric Blood and Cancer. 2019; 66.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. DuBois, SG; Mosse, YP; Fox, E; Kudgus, RA; Reid, JM; McGovern, R; Groshen, S; Bagatell, R; Maris, JM; Twist, CJ; et al. Clinical Cancer Research. 2018; 24:6142-6149.

NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Weiss, B; Plotkin, S; Widemann, B; Tonsgard, J; Blakeley, J; Allen, J; Schorry, E; Korf, B; Rosser, T; Goldman, S; et al. Neuro-Oncology. 2018; 20:i143-i143.

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Fisher, MJ; Belzberg, AJ; de Blank, P; De Raedt, T; Elefteriou, F; Ferner, RE; Giovannini, M; Harris, GJ; Kalamarides, M; Karajannis, MA; et al. American Journal of Medical Genetics, Part A. 2018; 176:1258-1269.